Understanding the Extracellular Matrix to Enhance Stem Cell-Based Tissue Regeneration
- PMID: 29499149
- PMCID: PMC5937845
- DOI: 10.1016/j.stem.2018.02.001
Understanding the Extracellular Matrix to Enhance Stem Cell-Based Tissue Regeneration
Abstract
The extracellular matrix is a biologically critical entity that has historically been poorly understood. Here we discuss how new tools for characterizing matrix composition and function enable us to design and deliver advanced matrices in vitro, to optimize regeneration, and in vivo, within a variety of tissues and organs.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
L.E.N. is a founder and shareholder in Humacyte, Inc., which is a regenerative medicine company. Humacyte produces engineered blood vessels from allogeneic smooth muscle cells for vascular surgery. L.E.N.’s spouse has equity in Humacyte, and L.E.N. serves on Humacyte’s Board of Directors. L.E.N. is an inventor on patents that are licensed to Humacyte and produce royalties for L.E.N.; patent numbers and associated patents include the following: 19,657,265, Tubular tissue-engineered constructs; 29,650,603, Tissue-engineered constructs; 39,556,414, Tissue-engineered constructs; 49,127,242, Tissue and organ graft bioreactor and method of operation; 58,198,245, Compositions and methods for soft tissue augmentation; 67,993,567, Method and system for aligning fibers during electrospinning; 77,943,378, Tissue engineering; 87,498,332, Therapy for cerebral vasospasm; 96,962,814, Decellularized tissue engineered constructs and tissues; and 106,537,567, Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells. L.E.N. has received an unrestricted research gift to support research in her laboratory at Yale. Humacyte did not fund these studies, and Humacyte did not influence the conduct, description, or interpretation of the findings in this report.
Figures

References
-
- Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet. 2016;387:2026–2034. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical